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1. Introduction 
1.1 Psychiatric disorders and infectious diseases 
Psychiatric disorders are a wide group of diseases with a heterogeneous aetiology (genetic 
predisposition, environmental factors, exposure to stress, for example). Several infectious 
agents preferentially affect the central nervous system and these infections are associated 
with psychic and neurologic symptomatology. It has been suggested that some infectious 
diseases can influence the development and the course of several psychiatric disorders. 
Infectious agents of zoonotic diseases with the ability to cause persistent infections of the 
central nervous system and influence the development and functions of this system include 
Toxoplasma gondii, Borrelia burgdorferi and Borna disease virus (BDV). Other neurotropic 
viruses that affect humans and which are associated with neurologic and psychiatric 
symptoms include herpes viruses, HIV and rabies virus, among others. Toxoplasma gondii is 
associated with cognitive dysfunctions in infected subjects (human and animals). Studies 
have shown that there is a direct statistical link between incidences of schizophrenia and 
toxoplasmosis infection. Several studies reported significantly higher seropositivity of this 
infection in schizophenic patients (Torrey & Yolken 2003). Lyme borreliosis is caused by the 
Gram-negative spirochete Borrelia burgdorferi, which has a high affinity with the central 
nervous system. There may be a long latent period between infection and the development 
of clinical neuropsychiatric symptoms. Several studies associated borreliosis with affective, 
anxiety (panic) and organic disorders and psychosis. A higher seropositivity was 
demonstrated in psychiatric patients compared to healthy individuals (Hájek et al., 2002). 
1.2 Borna disease virus characteristics and animal infection 
Borna disease virus (BDV) is an enveloped non-segmented negative-stranded RNA virus 
that belongs to the family Bornaviridae, order Mononegavirales. Examples of other virus 
families that belong to the order Mononegavirales are Filoviridae, Paramyxoviridae and 
Rhabdoviridae. Borna disease virus is a neurotropic virus that affects the central nervous 
system, especially limbic structures. Borna disease virus infects warm-blooded animals 
(birds and mammals, including humans). The clinical symptoms of BDV infection range 
from asymptomatic or a mild symptomatology to severe neurologic and behaviour 
disturbances and lethal non-purulent encephalitis. 
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The BDV genome consists of a linear non-segmented single-stranded RNA with negative 
polarity. The genome is divided into three main gene blocks: the first codes for 
nucleoprotein (N) and polymerase cofactors represented by p40 and p24 proteins, the 
second codes for matrix (M) and virus envelope proteins, represented by p16 and p56 
proteins, the third codes for the viral polymerase. The entry of BDV is via receptor-mediated 
endocytosis; protein p56 is sufficient for receptor recognition and virus entry (Briese et al., 
1994; Cubitt et al., 1994). The BDV ribonucleic protein is transported into the cell nucleus 
where BDV transcription and replication occur. The replication of this virus in host cells is 
typical of the family Bornaviridae (de la Torre et al., 1994). 
1.3 History of BDV infection 
The first description of Borna disease infection was found in seventeenth century literature 
that describes this disease as affecting horses; later, behavioural changes in other farm 
animals were described. By the twentieth century, many cases of this infection in farm 
animals had been described, especially in horses and later in sheep; this disease causes a 
high mortality rate in infected animals. Borna disease virus owes its name to the town Borna 
in Saxony (Germany), where a large number of military horses died during an epidemic of 
this infection in 1885. It was originally thought that BDV only infected horses and sheep; 
BDV infection has since been described in other species across the world, including birds, 
cats, cattle, primates, rats, mice and others.  
In the 1920s and 1930s the aetiology of Borna disease was discovered by Zwick and 
colleagues in Giessen (Germany). They successfully transmitted brain homogenates from 
naturally infected horses to experimental animals. Borna disease virus was isolated in the 
following years by Zwick, Siefried, Nicolau and Galoway (Durrwald & Ludwig, 1997).  
Borna disease virus antigens were isolated in the 1950s and 1960s (Durrwald & Ludwig, 
1997; Ludwid & Bode, 2000) and in 1976 viral antibodies were detected in humans (Ludwig, 
unpublished data from 1985 in psychiatric patients (Rott et al., 1985). In the 1990s, the 
structures of BDV and viral RNA were described and isolated, BDV was integrated into the 
order Mononegavirales and the new family Bornaviridae (Durrwald & Ludwig 1997, Ludwig 
& Bode 2000) was created. 
1.4 The course of BDV infection in animals 
The symptomatology of BDV infection in animals ranges from asymptomatic, to a mild 
subclinical infection to lethal meningoencephalitis. The majority of infected individuals have 
subclinical, mild symptoms and BDV infected hosts are generally asymptomatic carriers. Some 
infected subjects develop relapsing mood disorders and behaviour disturbances (changes in 
appetite and sleeping, apathy or aggressive behaviour and cognitive impairments such as in 
memory or learning functions, for example) or neurological symptoms (movement or posture 
impairments, cramps and motor disturbances). A minority of infected animals have a lethal 
course of BDV infection and die from non-purulent meningoencephalitis.The course of BDV 
infection is influenced by several factors, including the age of animal at the time of infection, 
its immune status, genetic background and the type of animal, among others. This viral 
infection is associated with neurological, behavioural, mood and cognitive changes. This 
symptomatology leads to the possible connection with human psychiatric disorders such as 
affective and psychotic disorders and the possibility that BDV infection could contribute to the 
aetiology of several psychiatric disorders. 
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1.5 Epidemiology of Borna disease virus infection 
Borna disease virus infection was originally believed to be limited in horses and sheep in 
endemic areas in Central Europe, especially in Germany. But over the years, the use of new 
diagnostics methods discovered the presence of natural BDV infections in other regions, 
such as Australia, the United States of America (Kao et al., 1993; Richt et al., 2000), China 
(Hagiwara et al., 2001), the United Kingdom (Reeves et al., 1998), Japan (Watanabe et al., 
2006), Israel (Teplitski et al., 2003), other European countries (Italy, Poland, Czech Republic, 
France, Switzerland) (Galabru et al., 2000; Pisoni et al., 2007) and others. Natural BDV 
infection was detected not only in horses and sheep but also in other animal species: cats 
(Berg et al., 2001; Reeves et al., 1998), dogs (Weissenbock et al., 1998), cattle (Watanabe et al., 
2006), birds (Berg et al., 2001), foxes (Dauphin et al., 2001), and ostriches (Weismann et al., 
1994). Borna disease virus infection differs in its course according to the species; the most 
serious form of Borna disease is described in horses and sheep with severe neurologic 
symptoms and high mortality rates, in contrast to other species (Ludwig & Bode 2000). 
1.6 The transmission of BDV infection  
There are several supposed routes of transmission of BDV infection between humans and 
animals: by direct contact with infectious secretions through the nasal mucosa (Durrwald & 
Ludwig 1997; Hatalski et al., 1997; Ludwig and Bode 2000; Richt et al., 1993, 2000, 2001), 
vertically during pregnancy (Hagiwara et al., 2000; Okamoto et al., 2003), and indirectly by 
infected (contaminated) food or water (Durrwald & Ludwig 1997; Hatalski et al., 1997; 
Ludwig & Bode 2000; Richt et al., 1993, 2000, 2001). Findings of BDV RNA and proteins in 
peripheral blood mononuclear cells indicate the possibility of hematogenous transmission 
(Solbrig et al., 2003; Vahlenkamp et al., 2000). Pisoni and colleagues reported the possible 
sexual transmission of BDV infection. They detected higher BDV seropositivity in sexually 
active female horses compared to lower BDV seropositivity in animals that had never had 
sexual contact (Pisoni et al., 2007). Human-to-human transmission of BDV infection is 
supported by several studies that described higher BDV positivity in mental health workers 
and family members who were in contact with BDV-positive psychiatric patients (Chen et 
al., 1999a). Some studies described higher BDV positivity in humans who were in contact 
with infected animals; this BDV positivity was positively correlated with the degree of 
contact with infected animals. These findings proved the animal-to human transmission of 
BDV infection, which is typical of zoonotic infections (Takahashi et al., 1997; Thomas et al., 
2005; Weismann et al., 1994).  
Infected rodents and wild birds are considered to be reservoirs of BDV infection (Berg et al., 
2001), but pets and farm animals represent a greater risk of human BDV infection because of 
the closer contact with them. Experimentally infected rodents developed persistent BDV 
infection, which is associated with the presence of the virus in saliva, urine and faeces. 
Borna disease virus was also found in the excrement of migrating birds. These reports 
suggest that wild birds could be a reservoir because of the possibility of water or food 
contamination by infected secretions.  
The most frequent route of BDV infection transmission is probably via contact with infected 
saliva or other secretions through the nasal mucosa. The olfactory route of BDV 
transmission is efficient; the olfactory bulbs in naturally infected horses show oedema and 
inflammation early in the course of infection. After infection, BDV initially replicates in the 
neuroreceptor cells of the olfactory epithelium; then, BDV spreads intra-axonally and trans-
synaptically towards olfactory structures and then preferentially to the limbic system. In the 
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nuclei of infected neurons, aggregates of virus material form Joest-Degen inclusion bodies 
that are typical of BDV infection. The spread of this virus is not just restricted to the limbic 
system; during later stages of infection BDV diffuses though the central nervous system and 
can be detected in oligodendrocytes, astrocytes, Schwann cells and ependymal cells in the 
peripheral nervous system. In the late stages of BDV infection the virus spreads 
centrifugally and virus markers can be detected in the peripheral nerves of all tissues. The 
spread of BDV infection within the CNS is mediated by ribonucleoprotein particles rather 
than by the enveloped virus. A minimum incubation period of 3 to 4 weeks is estimated for 
horses and sheep with nonspecific signs such as hyperthermia, anorexia, colic and 
constipation in the initial phase (Carbone et al., 1987; Gonzales-Dunia et al., 1997, 2000; 
Gosztonyi & Ludwig, 1984, 2001).  
1.7 Mechanism of action, persistent infection, and the course of infection 
Borna disease virus can cause persistent infection in the central nervous system. Persistent 
viral infection is characterized as circumstances in which the virus is not cleared but remains 
in the cells of infected individuals. There are three types of persistent viral infection: latent, 
chronic and slow infection. The latent type of persistent infection is typical of BDV. Latent 
infection is associated with a lack of demonstrable viral particles. The reactivation of 
persistent latent BDV infection can be triggered by several stimuli: super-infection by other 
infectious agents, trauma, stress factors, medication or other diseases that lead to changes in 
immune system. After reactivation, it is possible to detect viral structural proteins that 
interfere with neurotransmitter receptors and their functions.  During infection, BDV 
influences the central nervous system in several ways: firstly, there is a direct influence 
through the binding of viral proteins with neurotransmitter receptors (monoamine, 
serotonin and dopamine systems), and secondly there is an indirect influence though the 
immune response and inflammatory reactions. Both types of mechanisms contribute to 
neurotransmitter changes and lead to mood, emotional or behaviour changes in infected 
subjects, and they may also be associated with psychiatric disorders. The severity of clinical 
symptoms and the course of BDV infection depend on several factors: immune status and 
response of the host, the age at infection, and genetic vulnerability (predisposition) to the 
development of psychiatric disorders, among others (Dietrich et al., 1998). The third 
mechanism by which BDV can possibly influence CNS functions is due to the fact that viral 
infections are able to influence the human genome. Some human genetic material originates 
from viruses and viral sequences being assimilated into the host genome. After infection, 
BDV sequences are integrated into the genome of brain cells. These sequences are not 
heritable but they can cause mutations that interfere with brain functioning and can 
contribute to the development of psychiatric disorders (Feschotte, 2010). 
1.7.1 Borna disease virus and its influence on the central nervous system 
Animal models have been used to study and help explain the influence of BDV infection on 
the central nervous system. Changes in several neurotransmitter receptors have been 
described. Research on adult experimental rats has shown how BDV infection causes long-
term changes in cognition, emotions and behaviour. Research on neonatal animals has 
explained how BDV infection influences brain development with subsequent changes in 
behaviour and cognition. 
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Changes in the dopamine system of infected adult rats were described, where disturbances 
were found in the levels of dopamine in the caudate-putamen (D2 receptors) and the 
nucleus accumbens (D2 and D3 receptors): pre- and postsynaptic sites of dopamine 
receptors were damaged in the striatum, dopamine reuptake sites were reduced in the 
caudate-putamen and nucleus accumbens, postsynaptic D2 receptors were reduced in the 
caudate-putamen and D2 and D3 receptor binding was decreased in the nucleus accumbens. 
Postsynaptic dopamine receptors (D1 and D2) remain intact in the prefrontal cortex; this 
imbalance leads to D1 hypersensitivity and neurobehavioural disturbances in BDV-infected 
animals. Partial dopamine deafferentation and compensatory hyperactivity of the remaining 
striatal nerve terminals in the nigrostriatal projections are associated with locomotor activity 
and stimulant sensitivity. Decreased numbers of dopamine D2 and D3 receptors and the 
remaining numbers of D1 receptors in the striatum are associated with dyskinesias and 
dystonia (Solbrig et al., 1994, 1996, 2000, 2010). These changes in dopamine 
neurotransmission support a connection between BDV and neuropsychiatric disorders such 
as schizophrenia and addiction and extrapyramidal disorders. 
In addition to the altered dopamine system the dysfunction of serotonin and noradrenergic 
systems is present and is associated with other symptoms. There is evidence of a serotonin 
system dysfunction in the striatum and norepinephrine dysregulation in the prefrontal and 
anterior cingulate cortex. Changes caused by BDV infection include reduced serotonin 
transmission, which is associated with autistic disorders and depression.  
The course of BDV infection in adult rats is more severe in comparison to infected neonate 
rats, which have a milder symptomatology in BDV infection. These animals developed 
behaviour and cognitive changes, learning difficulties, increased motor activity, abnormal 
anxiety responses, deficits in motor coordination and postural stability and impairments in 
social behaviour, and they also showed abnormally early locomotor development. They also 
showed altered circadian rhythms and appetite changes. Damage to or dysfunction in the 
CNS of these animals is associated with direct viral effects on the morphogenesis of the 
hippocampus and cerebellum (Dietz et al., 2004; Pletnikov et al., 2000, 2001, 2002; Solbrig et 
al., 2010). Borna disease virus infection impairs synaptic plasticity, which is important for 
learning and memory (Volmer et al., 2007). 
Behaviour disturbances were reported in other experimentally infected animals: altered 
social and sexual behaviours such as abnormal dominance relationships and a failure to 
mate were described in primates (tree shrews and rhesus monkeys). Rhesus monkeys were 
initially hyperactive and later became apathetic (Sprankel et al., 1978; Stitz et al., 1980).  
Neonatal Borna disease virus infection in rats is associated with the activation of microglia 
and astrocytes and the loss of neurons in the dentate gyrus in the hippocampus, cortex and 
cerebellum (Gonzales-Dunia et al., 2000; Pletnikov et al., 2002; de la Torre, 2002). Ovanesov 
and colleagues were the first to find a significant increase in microglial activation and 
secondary neuronal loss (Ovanesov et al., 2008). Borna disease virus infection also affects 
astrocytes, which play an essential role in the maintenance of homeostasis in the CNS. Borna 
disease virus infection is also associated with impairment in the ability of astrocytes to take 
up glutamate; this impairment leads to increased levels of extracellular glutamate, the 
activation of NMDA receptors and an increased calcium influx, and results in neurotoxicity 
and cell death (Billaud et al., 2000).   
In the pathogenesis of Borna disease, Borna disease virus infection also plays an important 
role in the inflammatory reaction (the BDV-specific T-cell response and the activity of CD8+ 
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T-cells cause the destruction of virus-infected neurons). The inflammatory reaction is 
associated with the symptomatology of infection (Stitz et al., 1995).   
1.7.2 Viro-psycho-immunological disease model and schematic (in connection with 
psychiatric disorders) 
The connections between viral infections, stress and immune functions are described and 
explained by the viro-psycho-immunological disease model. Acute or chronic stress or other 
factors (other infections, diseases, immunosupressive medications, for example) cause 
changes in immune functions. These alterations in the immune system are responsible for 
the reactivation of latent forms of BDV infection in the central nervous system. The 
reactivation of BDV directly influences CNS function due to the affinity of viral proteins to 
neurotransmitter receptors and indirectly influences it via the inflammatory reaction, which 
also leads to changes in neurotransmission. Individuals with a greater vulnerability 
(predisposition) for developing psychiatric disorders (genetic disposition) can develop 
psychiatric symptoms (Dietrich et al., 1998) (see Figure 1). 
 
 
Fig. 1. Viro-psycho-immunological disease model of BDV infection and psychiatric 
disorders adapted from Dietrich et al., 1998 
1.8 Laboratory diagnosis of BDV infection  
The aims of laboratory diagnostics in BDV are the detection of BDV infection and the 
determination of infectious activity and its severity. Several questions can be asked: is the 
patient infected by BDV? Is this infection active? How intense or severe is this infection? Is 
treatment of BDV infection suitable? 
Patients with genetic 
predisposition 
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Borna disease virus antigens (Ag), antibodies (Ab), circulating immunocomplexes (CIC) and 
viral ribonucleic acid (RNA) can be isolated and detected in brain tissue, cerebrospinal fluid 
(CSF), serum,  plasma or in peripheral blood mononuclear cells (PBMCs).  
The original diagnostics for BDV infection consisted of the detection of viral Ab via 
serological methods, especially immunofluorescence assays (IFA). These methods, which 
only detected BDV Ab, were not very sensitive and were not able to detect acute phases of 
BDV infection. Enzyme-linked immunosorbent assays (ELISA) were based on recombinant 
viral proteins and were used in several studies to detect BDV Ab, but they showed a 
surprisingly low sensitivity, which could explain the differences found in the study results. 
The use of electrochemiluminescence immunoassays (ECLIA) did not show any great 
advantages in the diagnosis of BDV infection. 
Another laboratory method that has been used for the detection of BDV Ab is Western 
blotting (WB), but this was found to be less sensitive than new-generation ELISAs with 
native viral antigens. Positivity of BDV Ab can indicate a persistent form of infection (in the 
absence of active BDV infection) or previous contact with this infection, but not an acute 
state. The absence of BDV Ab in the serum does not mean the BDV infection result is 
negative; antibodies bind antigens and form circulating immunocomplexes.  
Antigenaemia indicates an acute and productive phase of infection. During this phase of 
BDV infection antibodies bind to the viral antigens and form CIC, which are measurable for 
weeks or months. The frequency and stability of BDV CIC make them easily available 
screening markers of BDV infection. By using the ELISA method, it is possible to detect viral 
Ag in plasma. The disadvantage of this method of detection is the very short period of 
antigenaemia in the acute phase of BDV infection and the high risk of false negative results 
after the formation of BDV CIC. 
Bode and colleagues developed an ELISA (triple ELISA) method that mainly detects BDV 
CIC but also free BDV antigens and antibodies (Bode et al., 2001).  
Several authors used the detection of viral RNA in PBMCs (peripheral blood mononuclear 
cells) in brain tissue via polymerase chain reaction (PCR) for the diagnosis of BDV 
infection. However, other researchers did not use this method for the diagnosis of BDV 
infection and do not recommend RNA detection as the best diagnostic tool. The first 
reason is due to the possibility of sample contamination during the laboratory procedure 
(although contamination should not occur when the detection of BDV RNA is performed 
according to international security instructions). The second reason is because the absence 
of BDV RNA in samples does not exclude the possibility of BDV infection, since RNA 
detection is less reliable than the detection of other virus particles (Ag or CIC) because of 
the low replication rate of this virus and the small amount of RNA in PBMCs. Also, the 
presence of BDV RNA in the brain does not necessarily reflect an active state of BDV 
infection (Bode et al., 2001, Sauder & de la Torre, 1998; Thakur et al., 2009; Wolff et al., 
2006). 
Currently, the detection of BDV CIC by ELISA and viral isolation from PBMCs are 
recommended as the best screening methods of active BDV infection because of their 
relative stability and frequency. The best indicators (markers) of viral disease are antigen 
ELISA and CIC ELISA, which also both correlate well with the severity of the BDV infection. 
The ELISA method for the detection of BDV CIC was developed by Bode and Ludwig (Bode 
et al., 2001). Table 1 shows a summary of the diagnostic methods.  
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Test Sample Diagnostic 
parameter 
Antigen Sensitivity Specificity Indicative 
of infection 
Indicative 
of disease 
Complement 
fixation 
serum Ab Native Low Good 
 
Low Poor 
Double 
diffusion 
serum Ab Native Low Good Low Poor 
IFA serum Ab Altered by 
fixation 
Good Very good Good Poor 
CSF   Poor Very good Very good Poor 
Cell ELISA serum Ab Altered by 
fixation 
Low Good Low Poor 
ECLISA serum Ab Recombinant Good Very good Good Poor 
Recombinant 
ELISA 
serum Ab Recombinant Good Good Good Poor 
Ab ELISA serum Ab Native Excellent Excellent Very good Poor 
Cell Ag 
ELISA 
PBMCs Ag Native Low Excellent Good Good 
Plasma Ag 
ELISA 
serum Ag Native Good Excellent Very good Excellent 
CSF Ag Native Low Excellent Very good Excellent 
CIC ELISA serum CIC Native Excellent Excellent Excellent Excellent 
WB serum Ab, Ag Denatured Low Very good Good Poor 
CSF   Poor Very good Very good Very good 
Flow 
cytometry 
PBMCs Ag Mild 
fixation 
Good Very good Good Good 
RT-PCR PBMCs RNA  Very good Excellent Very good Poor 
brain RNA  Good Excellent Very good Poor 
serum RNA  Low Excellent Very good Good 
Isolation 
 
PBMCS virus  Poor Excellent Excellent Very good 
brain virus  Poor Excellent Excellent Very good 
Table 1. Diagnostic tools for the detection of Borna disease virus infection in humans 
(Thakur et al., 2009), abbreviations explained in text 
1.9 Factors influencing BDV positivity 
Borna disease virus positivity in psychiatric patients ranges from negative to highly 
positive. These differences in positivity can be caused by several factors; features of the 
psychiatric population (age, diagnosis, severity of the psychopathology, immune status), 
geographical region, differences in specificity and sensitivity of the laboratory methods used 
and which diagnostic parameters (Ab, Ag, CIC or RNA) are detected and which biological 
material (brain tissue, cerebrospinal fluid, serum) is used. Other factors include the seasonal 
occurrence of BDV infection and contact with animals. 
1.9.1 BDV positivity and age 
Several studies showed a higher rate of BDV positivity in younger individuals. Patti and 
colleagues investigated BDV CIC positivity in children in Italy; BDV positivity was detected 
in 57%. The prevalence of BDV infection was found to be significantly greater in children, 
particularly in the third year of life; then it decreased until 15 years of age, where another 
increase was observed (Patti et al., 2008). Another study performed by Scholbach and 
colleagues demonstrated higher rates of BDV Ag and CIC positivity in children. There were 
two age intervals of peak BDV positivity: the first was a peak at 6 months old and the 
www.intechopen.com
 
Borna Disease Virus and Psychiatric Disorders: Can Viruses Influence Psychiatric Disorders? 
 
253 
second was a peak around 2-3 years old. These findings support the possible vertical 
transmission of BDV infection. Two other possible explanations for the greater prevalence of 
BDV infection in children than in adults are the less well-developed immune status of 
children and the fact that children of 2-3 years old are more likely to have greater contact 
with animals and their secretions, which are associated with a greater risk of BDV 
transmission (Scholbach et al. 2008). 
1.9.2 BDV positivity and the types of psychiatric disorder 
Borna disease virus infection was detected in psychiatric patients with various disorders; the 
majority of these studies detected BDV in patients with affective (bipolar and depressive) 
disorders and psychotic disorders (schizophrenia and schizoaffective disorders). The 
highest rate of BDV positivity was found in patients with bipolar and depressive disorders 
(Ferszt et al., 1999). Rybakowski and colleagues reported significantly higher rates of BDV 
Ab seropositivity in Polish psychiatric patients with affective-anxiety spectrum disorders 
and mental retardation than in healthy controls, and the rate of BDV seropositivity was 
significantly higher in patients with recent disease onset compared to past disease onset 
(10.2% vs. 1.6%) (Rybakowski et al., 2001). 
1.9.3 BDV positivity and psychopathology 
Several research groups reported an association between BDV positivity and the type or 
severity of the psychopathology. In a study performed by Iwahashi and colleagues, a 
significantly higher rate of BDV seropositivity was detected in schizophrenic patients with a 
negative symptomatology than in patients with positive symptoms (Iwahashi et al., 1998). 
Waltrip and colleagues detected a higher rate of BDV seropositivity in schizophrenic patients 
with deficit syndrome than in patients with non-deficit syndrome (Waltrip et al., 1997). 
Bode and colleagues detected a higher rate of BDV seropositivity (more than 30%) in 
patients with major depressive disorder and a lower rate of positivity (8%) in patients with 
dysthymia (Bode et al., 1993). Ferszt and colleagues confirmed the higher rate of BDV 
antigenaemia in patients with affective disorders. The number of previous depressive 
episodes with symptoms including fatigue and concentration difficulties was positively 
related to BDV Ag positivity (Ferszt et al., 1999). Bode and colleagues found significantly 
higher rates of BDV Ag and CIC positivity (including higher values) in severely depressed 
patients during an acute crisis and lower rates of BDV Ag and CIC positivity (lower rates 
and lower amounts of Ag and CIC) in patients with moderate depression. The severity of 
depressive symptoms correlated with the concentration and duration of antigenaemia (Bode 
et al., 2001). In study reported by Rackova and colleagues, a significantly higher rate of BDV 
CIC positivity was found in psychiatric patients with a more severe psychopathology than 
in patients with a milder symptomatology, as measured by psychiatric scales (Rackova et 
al., 2009). 
1.9.4 Regional occurrence of BDV infection 
Naturally occuring Borna disease virus infection is still confined to several areas of Central 
Europe, these regions are endemic for this infection. The presence of BDV infection in 
animals and humans has been detected not only in European areas but across the world 
(China, Japan, Israel and several other countries) (Durrwald & Ludwig 1997, Ludwig & 
Bode 2000). 
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1.9.5 BDV positivity and laboratory methods used 
The high variability found for BDV positivity in humans can be influenced by the laboratory 
method used since they differ in terms of sensitivity and specificity. Another factor that can 
influence the detection of BDV infection is the infectious marker used: antibody, antigen, 
circulating immunocomplex or RNA.  
The detection of BDV CIC by ELISA has shown a 10-fold higher incidence of BDV infection 
than was estimated for BDV Ab positivity by the immunofluorescence method in psychiatric 
patients with affective disorders. The rates of positivity of BDV Ab by IFA were 11% and 
20% in patients with depression and 2% in blood donors vs. CIC positivity of 62%, 52% and 
24% in the same groups (Bode et al., 2001). Similar results were reported by Bode and 
colleagues in 1994, where  BDV Ab positivity was detected in 20% of psychiatric patients 
compared to the higher positivity of BDV Ag in 40-50% of the same psychiatric patients 
(Bode et al., 1994). Wolff and colleagues did not confirm these results. They analysed plasma 
samples with a high reactivity in the ELISA assay (high positivity of BDV antigens) by 
immunoaffinity purification and highly sensitive real-time RT-PCR (polymerase chain 
reaction): neither method provided any evidence for the presence of viral proteins or nucleic 
acids (Wolff et al., 2006). 
1.9.6 Seasonal occurrence of BDV infection  
Borna disease virus infection shows a seasonal prevalence, being more frequent in spring 
and early summer. Significantly higher numbers of seropositive animals (especially sheep 
and horses) have been detected during these periods and a higher occurrence of clinical 
cases was also observed (Durrwald & Ludwig 1997; Ludwig & Bode 2000; Staeheli et al., 
2000; Vahlenkamp et al., 2002). The number of animals that become infected and succumb to 
the disease differs each year, but no correlation has been described between the seasonal 
occurrence of BDV in animals and humans. 
1.9.7 Contact with animals 
Several studies have described an association between the prevalence of BDV infection in 
humans and contact with animals, which are potential reservoirs of BDV infection. 
Weismann and colleagues reported a significantly higher rate of BDV antibody positivity 
(46%) in workers exposed to infected ostriches compared to controls (10%). There was a 
strong positive correlation between the intensity of exposure and the rate of seropositivity 
(Weismann et al., 1994). Takahashi and colleagues found a significantly higher rate of BDV 
seropositivity (from 2.6% to 14.8%) in blood donors from regions containing concentrations 
of horse farms compared to the BDV seropositivity of 1% in blood donors from other 
regions (Takahashi et al., 1997). These findings support the possible animal-to-human 
transmission of BDV infection. In contrast, another study from Bangladesh did not confirm 
this hypothesis. The authors surveyed horses and their caretakers for BDV antibody 
positivity and found a BDV positivity of between 25-30% in the horses but none of 
caretakers were positive for BDV (Khan et al., 2000). Thomas and colleagues measured BDV 
seroprevalence in agricultural workers in the United Kingdom. The seroprevalence was 
2.3% in 1994, 3.1% in 1996 and 2.6% in 1999. People living or working on livestock farms had 
a higher rate of seroprevalence (2.6%) than those on mixed (2.3%) or arable (1.6%) farms, but 
this was not statistically significant. Exposure to horses, sheep and cats did not increase the 
risk of seropositivity. Furthermore, the seropositive people were not more likely to report 
symptoms of psychiatric morbidity (Thomas et al., 2005). 
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1.9.8 Other factors and BDV positivity 
The activation of persistent BDV infection can be triggered by several stimuli (super-
infection by other infectious agents and immunosuppressive medication, among others) that 
affect the immune system. This hypothesis (claim) is supported by studies reporting a 
higher rate of BDV positivity in HIV patients (Auwanit et al., 1996; Bode et al., 1992; Cotto et 
al., 2003). A lower rate of BDV seropositivity (4-8%) was detected in the early stages of HIV 
infection, which then increased (13.9%) during later stages of this disease (Bode et al., 1992).  
1.10 BDV and psychiatric disorders 
Borna disease virus infection in animals is characterized by various behavioural changes, 
such as changes in social behaviour, apathy, aggressive behaviour, changes in appetite and 
weight, and cognitive impairment, amongst others. Because these behavioural disturbances 
of naturally and experimentally BDV-infected animals resemble psychiatric symptoms and 
disorders in humans, especially affective disorders, early studies investigated a possible link 
between patients with these diagnoses and BDV infection. The possible connection between 
BDV infection and psychiatric disorders is explained in the viro-psycho-immunological 
model, shown in Figure 1 (Dietrich et al., 1998). 
The earliest work that suggested a link between BDV infection and human psychiatric 
disorders was in 1985. Rott and colleagues examined serum samples from 979 psychiatric 
patients and 200 healthy volunteers for the presence of BDV Ab by indirect 
immunofluorescence. Borna disease virus antibodies were found in 16 of the psychiatric 
patients but none of the healthy volunteers. The patients who had positive serum samples 
also had a history of affective disorders (Rott et al., 1985). 
Since 1985, several studies have demonstrated significantly higher rates of BDV infection 
positivity in psychiatric patients compared to healthy individuals, but several studies did 
not confirm these results. The rate of BVD positivity in psychiatric patients ranged from 
negative to highly positive (almost 100% in patients with affective disorders).  
Several researchers found a significant association between BDV positivity (levels of BDV 
Ag and CIC) and severity of the psychopathology (Bode et al., 2001; Ferszt et al., 1999; 
Rackova et al., 2009) and between BDV seropositivity and negative symptoms in 
schizophrenia (Iwahashi et al., 1998; Waltrip et al., 1997). Borna disease infection is 
associated with a chronic course of the disease without full remission and with recurring 
psychiatric disorders. The reactivation of persistent BDV infection is caused by immune 
changes and influences neurotransmitter systems and, in vulnerable individuals, it can 
contribute to the onset of a new phase of a psychiatric disorder and influence its course. 
1.11 Therapy of BDV infection 
Non-pharmacological procedures that could lead to the elimination of BDV infection were 
used in the past. The separation of infected animals and improvements in hygiene were 
recommended, but these procedures only decreased the risk of BDV infection spreading but 
did not eliminate the infection. Vaccination with killed vaccines and then live vaccines 
became available in the twentieth century, but both types of vaccine were shown to be 
ineffective against the Borna disease virus. Vaccination against persistent viral infection in 
the central nervous system cannot be recommended (Ludwig & Bode, 2000). 
Antiviral medications were also tested for the treatment of BDV infection. 
Hexamethylenetetramine was used for the treatment of horses, and then later hexamine 
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(Ludwig & Bode, 2000), ribavirine (Jordan et al., 1999), interferon alpha or beta 
(Hallensleben et al., 1999; Staeheli et al., 2001) and cyclosporine A (Stitz et al., 1989), but no 
effect was found on BDV infection. Some of these preparations showed a decrease in BDV 
replication in vitro, but they did not show efficacy in vivo.  
Bechter and colleagues described several cases where an improvement in the psychic status 
of psychiatric patients with schizophrenia and depression was shown after cerebrospinal 
fluid filtration (Bechter et al., 2000). 
Currently, amantadine is used for the treatment of BDV infection. Amantadine is a non-
competitive N-methyl D-aspartate-type glutamate receptor antagonist that also binds to 
nicotinic acetylcholine receptors. Amantadine inhibits BDV replication. Initially, 
amantadine-sulphate was used in the prophylaxis of influenza A (Kandel et al., 2001), in the 
treatment of Parkinson’s disease (Brenner et al., 1989), hepatitis C (Adinolfi et al., 2003) and 
cocaine dependence (Kampman et al., 2000). A mild antidepressant effect of amantadine 
was found in a double-blind study when compared to amitriptyline and a placebo in 
patients with depression without BDV infection (Vale et al., 1971). Amantadine is a 
virostatic agent effective in the treatment of BDV infection, since it influences BDV 
replication in vivo. 
The use of amantadine was first described in two case reports in 1991 and 1997 in the 
treatment of two psychiatric patients with bipolar affective disorder, where improvements 
in the psychiatric status of both patients were associated with the decrease and elimination 
of BDV positivity (Bode et al., 1997). Later, several open trials were performed to test the 
efficacy of this drug in psychiatric patients and amantadine-sulphate was proven to be 
effective in the treatment of depression in BDV positive patients (Dietrich et al., 2000; Ferszt 
et al., 1999); the improvement in the depressive symptomatology was correlated with a 
decrease in BDV infection positivity. The patients were treated with 200 mg of amantadine 
per day for 12 weeks, and the majority showed significant improvements (clinical response) 
within the first three weeks (Dietrich et al., 2000). Ohlmeier and colleagues published the 
results of a double-blind trial that evaluated the effect of amantadine in the treatment of 
patients with the manic phase of bipolar disorder and amantadine reduced manic 
symptoms in BDV-infected bipolar patients (Ohlmeier et al., 2008).  
2. Aims and methods 
2.1 Aims 
Because of the marked differences in BDV positivity in patients with different psychiatric 
disorders, we decided to review available studies on the detection of BDV infection in 
psychiatric disorders and attempt to explain these differences.  
2.2 Method 
We undertook a systematic review to determine the rate of positivity of Borna disease virus 
infection in psychiatric patients. 
2.3 Data sources 
PubMed, Medline, Journals@Ovid Full Text, Evidence-Based Medicine and the Cochrane 
database (1985-2011) were searched using the keywords ‘Borna disease virus’, ‘psychiatric 
disorders’ and ‘prevalence’ in conjunction with each of the following organic disorders, 
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addictions, psychotic disorders, affective disorders and anxiety disorders. Due to variations 
in the laboratory methods, materials and study groups used, a meta-analysis was not 
possible. 
2.4 Study selection 
The inclusion criteria were studies published from 1985 to January 2011, the study 
participants: psychiatric patients, investigation: antibody, antigen, circulating 
immunocomplexes or viral RNA, material: serum, peripheral blood cells, cerebrospinal 
fluid, brain tissue, and outcomes: prevalence data. 
3. Results 
We identified 53 studies published from 1985 to July 2011 describing Borna disease virus 
positivity in psychiatric patients (psychiatric disorders, affective and psychotic disorders, 
addictions, neurotic disorders), 29 studies investigated viral antibodies in the serum, 23 BDV 
RNA in peripheral blood cells, 4 detected circulating immunocomplexes, viral antigens and 
antibodies in serum, 2 detected BDV RNA in cerebrospinal fluid (CFS), 5 detected BDV 
RNA in brain tissue and 8 studies detected BDV RNA and Ab. The prevalence of BDV 
infection in these studies ranged from 0 to 100% for patients with bipolar affective disorder.  
Between 1985 and 1993 the presence of BDV infection in groups of patients with various 
neuropsychiatric disorders was detected using IFA for BDV Ab. The majority of the studies 
identified found BDV in patients with schizophrenia and affective disorders. 
3.1 Borna disease virus infection and organic disorders 
Borna disease virus infection causes cognitive impairment (memory and learning 
impairment) in infected experimental animals. This impairment is linked to cholinergic loss 
in the forebrain and is associated with the pathology of Alzheimer’s disease (Solbrig et al., 
2010). Only a few studies reported BDV positivity in organic disorders, especially dementia. 
We identified five studies that detected the presence of BDV infection in patients with 
vascular and Alzheimer’s dementia; the rate of BDV positivity ranged from 0% to 1% (see 
Table2). 
 
Authors Country Method/marker Sample Diagnosis  Total no. No. and % of 
positives 
De la Torre  
et al., 1996 
USA PCR/Ag, RNA Brain  Alzheimer’s disease 7 0/0% 
Sauder  
et al., 1996 
Germany WB/Ab Serum Alzheimer’s, 
vascular and other 
organic disorders 
Control 
34 
 
 
203 
7/20.5% 
 
 
3/1.4% 
Igata et al., 
1998 
Japan IFA/Ab Serum Vascular dementia 
Control 
10 
36 
0/0% 
4/11% 
Yamaguchi  
et al., 1999 
Japan ECLIA/Ab Serum Alzheimer’s disease
Vascular dementia 
Control 
46 
89 
917 
0/0% 
1/1.12% 
10/1.09% 
Czygan  
et al., 1999 
Germany RT-PCR/RNA Brain Alzheimer’s disease
Control  
14 
52 
0/0% 
0/0% 
Table 2. Studies that detected BDV infection in patients with organic disorders  
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3.2 Borna disease virus infection and addiction 
Borna disease virus influences dopaminergic neurotransmission, including the reward 
system, which plays a crucial role in the pathology of addictive disorders. We found four 
studies that detected BDV infection in addicted patients. Only one study detected BDV 
positivity in addicted patients at the start of detoxification and at the end of treatment. 
Rackova and colleagues demonstrated BDV CIC positivity in 36.6% and 42.9% of patients 
with alcohol and drug abuse; the positivity of BDV infection was not significantly higher 
than in healthy individuals (Rackova et al., 2010). The rate of BDV positivity ranged from 
negative results to positivity in 42.9% (see Table 3).  
 
Authors Country Method/marker Sample Diagnosis  Total 
no. 
No. and % of 
positives 
Sauder  
et al., 1996 
Germany WB/Ab Serum Alcohol and drug 
addictions  
Control 
22 
 
203 
1/ 4.5% 
 
3/1.4% 
Yamaguchi  
et al., 1999 
Japan ECLIA/Ab Serum Alcohol 
addictions 
Control 
42 
917 
1/ 2.38% 
10/1.09% 
Czygan  
et al., 1999 
Germany RT-PCR/RNA Brain tissue Addictions 
Control 
27 
52 
0/0% 
0/0% 
Rackova  
et al., 2010 
Czech 
Republic 
ELISA/CIC Plasma Alcohol and drug 
addictions  
Control 
41 
28 
127 
15/36.6% 
12/42.9% 
47/37.3% 
Table 3. Studies that detected BDV infection in patients with alcohol and drug addictions 
3.3 Borna disease virus infection and psychotic disorders (schizophrenia, 
schizoaffective disorders) 
Borna disease virus infection causes changes in dopaminergic neurotransmission in adult 
experimental animals and influences brain development in infected neonatal animals; these 
changes are important in the aetiology of psychotic disorders in humans. We identified 29 
studies that detected BDV infection in patients with schizophrenia or schizoaffective 
disorders, 13 studies that detected BDV RNA, 9 that detected BDV Ab and 7 that detected 
both infectious markers: Ab and RNA. The rate of BDV infection positivity ranged from 0% 
to 63.6% in schizophrenic patients and from 0% to 13.86% in control groups of healthy 
individuals (see Table 4 and 5). 
3.4 Borna disease virus infection and affective disorders (depressive disorder, bipolar 
affective disorders) 
The first studies to detect BDV positivity in psychiatric patients reported higher rates of 
BDV positivity in patients with recurring affective disorders. We found 19 studies that 
described BDV positivity in patients with affective disorders (depressive and bipolar 
disorders, dysthymia), 8 studies that examined BDV RNA, 7 studies that detected BDV Ab,         
2 studies that detected BDV RNA and Ag and 1 study that detected BDV CIC, Ag and Ab. 
The rate of BDV infection positivity ranged between 0% and 90% in patients with affective 
disorders. The highest positivity rate was reported in patients with bipolar depression and 
severe psychopathology. The rate of BDV infection was from 0% to 32% in the control group 
of healthy individuals (see Table 6). 
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Authors Country Method/marker Sample Diagnosis  Total no. No. and % of 
positives 
Waltrip  
et al., 1995 
USA WB/Ab Serum Schizophrenia 
Control 
90 
20 
13/14.4% 
0/0% 
Sauder  
et al., 1996 
Germany WB/Ab Serum Schizophrenia 
Control 
114 
203 
16/11.42% 
3/1.4% 
Kubo  
et al., 1997 
Japan IFA/Ab 
WB/Ab 
Plasma Schizophrenia 
Control 
179 
70 
2/1.1% 
0/0% 
Waltrip  
et al., 1997 
USA WB/Ab Serum Negative 
schizophrenia 
Positive 
schizophrenia 
15 
49 
5/33.3% 
4/8.2% 
Deuschle 
et al., 1998 
Germany EIA/Ag, Ab CSF Schizophrenia ? 0/0% 
Iwahashi  
et al., 1998 
Japan WB/Ab Serum Schizophrenia 
Control  
67 
31 
30/44.8% 
0/0% 
Chen  
et al., 1999a 
Taiwan WB/Ab Plasma Schizophrenia 
Family members 
Mental health 
workers 
Control 
314 
132 
82 
274 
38/12.1% 
16/12.1% 
8/9.8% 
8/2.9% 
Yamaguchi  
et al., 1999 
Japan ECLIA/Ab Serum Schizophrenia 
Control 
845 
917 
26/3.08% 
10/1.09% 
Tsuji  
et al. 2000 
Japan WB/Ab Plasma Schizophrenia 
Control 
229 
229 
0/0% 
0/0% 
Selten  
et al., 2000 
Netherland
s 
IFA/Ab Serum Schizophrenia 
Control 
26 
29 
3/11% 
6/21% 
Fukuda  
et al., 2001 
Japan WB/Ab Plasma Schizophrenia 
Control 
45 
45 
2/4% 
1/2% 
Yang  
et al., 2003 
China WB/Ab Serum Schizophrenia 
Control 
116 
? 
10/8.6% 
0/0% 
Terayama  
et al., 2003 
Japan WB/Ab Serum Schizophrenia 
Control 
32 
25 
7/21.9% 
1/4% 
Matsunaga  
et al., 2005 
Japan RIA/Ab 
WB/Ab 
Serum Schizophrenia 
Control 
57 
41 
8/14% 
2/1% 
Na  
et al., 2009 
Korea IFA/Ab Serum Schizophrenia 
Control 
60 
60 
0/0% 
0/0% 
Karakose 
et al., 2011 
Turkey ELISA/Ab Serum Schizophrenia 
Control 
207 
137 
66/31.88% 
19/13.86% 
Table 4. Studies that detected BDV Ab in patients with schizophrenic disorders 
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Authors Country Sample Diagnosis  Total no. No. and % of 
positives 
Sierra-Honigmann 
et al., 1995 
USA CSF Schizophrenia  48 0/0% 
Igata-yi  
et al., 1996 
Japan Plasma 
PBMCs 
Schizophrenia 
Control  
49 
36 
5/10.2% 
0/0% 
Sauder  
et al., 1996 
Germany Plasma 
PBMCs 
Schizophrenia 
Control  
11 
23 
7/63.6% 
0/0% 
Kubo  
et al., 1997 
Japan Plasma 
PBMCs 
Schizophrenia 
Control 
? 
12 
0/0% 
0/0% 
Lieb  
et al., 1997 
Germany Plasma 
PBMCs 
Schizophrenia 
Schizoaffective disorders 
59 
10 
0/0% 
0/0% 
Richt  
et al., 1997 
Germany Plasma 
PBMCs 
Schizophrenia 
 
26 0/0% 
Iwahashi  
et al., 1997 
Japan Plasma 
PBMCs 
Schizophrenia 
Control  
67 
31 
6/8.9% 
1/3.2% 
Salvatore  
et al., 1997 
USA, Europe Brain Schizophrenia 17 9/53% 
Haga  
et al., 1997 
Japan Brain Schizophrenia 
Control 
9 
31 
3/33.3% 
2/6.5% 
Iwata  
et al., 1998 
Japan Plasma 
PBMCs 
Schizophrenia 
Control  
77 
84 
3/4% 
2/2% 
Czygan  
et al., 1999 
Germany Plasma 
PBMCs 
Schizophrenia 
Control 
13 
52 
0/0% 
0/0% 
Kim  
et al., 1999 
Korea Plasma 
PBMCs 
Schizophrenia 39 0/0% 
Chen  
et al., 1999b 
Taiwan Plasma 
PBMCs 
Schizophrenia 
Mental health workers 
Control 
74 
45 
69 
10/14% 
7/15% 
1/1,4% 
Nakamura  
et al., 2000 
Japan Brain Schizophrenia 
Control 
4 
2 
2/50% 
0/0% 
Tsuji  
et al., 2000 
Japan Plasma 
PBMCs 
Schizophrenia 
Control  
229 
229 
4/1.8% 
1/0.6% 
Fukuda  
et al., 2001 
Japan Plasma 
PBMCs 
Schizophrenia 
Control 
45 
45 
0/0% 
0/0% 
Kim  
et al., 2003 
Korea Serum Schizophrenia 62 0/0% 
Nunes  
et al., 2008 
Brazil Plasma 
PBMCs 
Schizophrenia, 
schizoaffective disorders 
Relatives with psychiatric 
disorders 
Relatives without 
psychiatric disorders 
Control 
27 
 
24 
20 
27 
12/44.4% 
 
9/37.5% 
10/50% 
4/14.8% 
Na  
et al., 2009 
Korea Plasma 
PBMCs 
Schizophrenia 
Control 
60 
60 
0/0% 
0/0% 
Karakose  
et al., 2011 
Turkey Plasma 
PBMCs 
Schizophrenia 
Control 
207 
137 
0/0% 
0/0% 
Table 5. Studies that detected BDV RNA in patients with schizophrenic disorders 
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Authors Country Method/marker Sample Diagnosis  Total no. No. and % of 
positives 
Amsterdam  
et al., 1985 
USA IFA/Ab Serum Unipolar and 
bipolar 
depression 
Control 
265 
 
105 
12/4.5% 
 
0/0% 
Bode  
et al., 1993 
Germany IFA/Ab Serum Major depression 
Neurotic 
depression, 
dysthymia 
? 
? 
?/30% 
?/8% 
Fu  
et al., 1993 
Japan WB/Ab Serum Affective disorders 
Control 
138 
117 
9/6.5% 
1/0.9% 
Sauder  
et al., 1996 
Germany WB/Ab 
 
Serum Affective disorders 
Control 
52 
203 
6/11.5% 
3/1.4% 
Bode  
et al., 1994 
Germany RT-PCR/RNA Plasma 
PBMCs 
Depression 
Control 
3 
10 
2/66% 
0/0% 
Igata-yi  
et al., 1996 
Japan RT-PCR/RNA Plasma 
PBMCs 
Depressive 
disorders 
Control 
6 
36 
1/16.4% 
0/0% 
De la Torre  
et al., 1996 
USA RT-PCR/RNA, 
Ag 
Brain Depressive 
disorders 
36 4/11.1% 
Kubo  
et al., 1997 
Japan IFA/Ab Plasma Mood disorders 
Control 
123 
70 
0/0% 
0/0% 
Lieb  
et al., 1997 
Germany RT-PCR/RNA Plasma 
PBMCs 
Depressive 
disorders 
Bipolar disorders  
41 
10 
0/0% 
0/0% 
Iwata  
et al., 1998 
Japan RT-PCR/RNA Plasma 
PBMCs 
Affective disorders 
Control 
49 
84 
2/4% 
2/2% 
Deuschle  
et al., 1998 
Germany RT-PCR/RNA CSF Recurrent 
depressive 
disorders 
32 3/9.4% 
Yamaguchi  
et al., 1999 
Japan ECLIA/Ab Serum Affective disorders 
Control 
251 
917 
9/3.59% 
10/1.09% 
Czygan  
et al., 1999 
Germany RT-PCR/RNA Brain Affective disorders 
Control 
11 
52 
0/0% 
0/0% 
Kim  
et al., 1999 
Korea RT-PCR/RNA Plasma 
PBMCs 
Bipolar disorders 
Depressive 
disorders 
33 
9 
0/0% 
0/0% 
Fukuda  
et al., 2001 
Japan RT-PCR/RNA Plasma 
PBMCs 
Affective disorders 
Control 
45 
45 
1/2% 
0/0% 
Fukuda  
et al., 2001 
Japan WB/Ab Plasma Affective disorders 
Control 
45 
45 
1/2% 
0/0% 
Terayama  
et al., 2003 
Japan WB/Ab Serum  Mood disorders 
Control 
33 
25 
9/27.3% 
1/4% 
Bode  
et al., 2001 
Germany ELISA/CIC, Ag
IFA/Ab 
Plasma Affective disorders 
 
 
 
 
187 
 
 
62% CIC, 11% 
Ab, 15% Ag 
103 52% CIC, 20% 
Ab, 23% Ag 
Control 100 24% CIC, 2% 
Ab, 0 Ag 
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Authors Country Method/marker Sample Diagnosis  Total no. No. and % of 
positives 
Bode  
et al., 2001 
Germany ELISA/CIC, Ag
IFA/Ab 
Plasma Severe depression 28 90% CIC 
Mild depression 28 90% CIC 
Control 65 32% CIC 
Matsunaga  
et al., 2005 
Japan WB, RIA/Ab Serum Mood disorders 
Control 
80 
41 
11/13.75% 
2/1% 
Na  
et al., 2009 
Korea RT-PCR/RNA 
IFA/Ab 
Plasma 
PBMCs 
Affective disorders 
Control 
138 
60 
0/0% 
0/0% 
Table 6. Studies that detected BDV infection in patients with affective disorders 
3.5 Borna disease virus infection and neurotic disorders 
Only a few studies reported BDV positivity in neurotic disorders: we identified 10 studies 
and 7 of them examined patients with chronic fatigue syndrome. Six studies detected BDV 
Ab, two detected BDV RNA and one detected both RNA and Ab markers. The rate of BDV 
positivity ranged from 0% to 34% in psychiatric patients and between 0% and 5.9% in 
healthy controls (see Table 7). 
 
Authors Country Method/marker Sample Diagnosis  Total No No and % of 
positive 
Sauder  
et al., 1996 
Germany WB/Ab Serum Neurotic, 
personality 
disorders 
Control 
54 
 
203 
8/14.8% 
 
3/1.4% 
Bode  
et al., 1994 
Germany RT-PCR/RNA Serum Panic disorder 
OCD 
Control 
1 
1 
10 
0/0% 
1/100% 
0/0% 
Nowotny & 
Windhaber, 
1997 
Germany ? Serum Panic disorders 
Control 
55 
34 
4/7.3% 
2/5.9% 
Bode  
et al., 1992 
Germany, 
USA 
IFA/Ab Serum Chronic fatigue 
syndrome 
50 0/0% 
Nakaya  
et al., 1996 
Japan RT-PCR/RNA Plasma 
PBMCs 
Chronic fatigue 
syndrome 
25 8/32% 
Kitani  
et al., 1996 
Japan ELISA/Ab Serum Chronic fatigue 
syndrome 
89 30/34% 
Gow  
et al., 1997 
UK WB/Ab Serum Chronic fatigue 
syndrome 
Control  
21 
 
13 
2/10% 
 
0/0% 
Evengard  
et al., 1999 
Sweden WB, ELISA/Ab
RT-PCR/RNA 
Serum 
Plasma 
PBMCs 
Chronic fatigue 
syndrome 
18 0/0% 
Yamaguchi  
et al., 1999 
Japan ECLIA/Ab Serum Chronic fatigue 
syndrome 
Control  
75 
 
917 
0/0% 
 
10/1.09% 
Li  
et al., 2003 
China WB/Ab Plasma Chronic fatigue 
syndrome 
Control 
61 
 
73 
7/11.8% 
 
0/0% 
Table 7. Studies that detected BDV infection in patients with anxiety disorders and OCD 
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3.6 Borna disease virus and unspecified psychiatric disorders 
Several studies examined psychiatric patients with various diagnoses and it was not 
possible to divide these groups according the diagnosis. We found 17 studies that detected 
BDV infection in unspecified psychiatric (or neuropsychiatric) patients, 5 studies that 
detected BDV Ab, 1 study that detected Ab and Ag, 1 that only detected Ag, 7 studies that 
detected BDV RNA, 2 that detected BDV CIC and 1 study detected BDV Ab and RNA. The 
rate of BDV positivity ranged between 0% and 66.7% in psychiatric patients and between 0% 
and 37.3% in healthy individuals (see Table 8).   
 
Authors Country Method/marker Sample Diagnosis  Total No No and % of 
positive 
Rott  
et al., 1985 
Germany, 
USA 
IFA/Ab Serum Psychiatric patients
Control 
979 
200 
16/1.6% 
0/0% 
Bode  
et al., 1992 
Europe, 
USA, Africa
IFA, 
immunoprecipit
ation/ Ab, Ag 
Serum Chronic diseases of 
the brain, immune 
system, infection 
(HIV, parasitosis) 
Control 
Total 
number 
3000 
?/13-14% 
 
 
 
?/2% 
Bode  
et al., 1993 
Germany IFA/Ab Serum Psychiatric patients
(screening) 
70 1-3/2-4% 
Bode  
et al., 1993 
Germany IFA/Ab Serum Psychiatric patients
(follow-up test) 
70 14/20% 
Kishi  
et al., 1995 
Japan WB, ELISA/Ab Serum Control 100 1/1% 
Kishi  
et al., 1995 
Japan RT-PCT/RNA Plasma 
PBMCs 
Psychiatric patients
Control 
60 
100 
72 
22/37% 
5/5% 
3/ 4.2% 
Bode  
et al., 1996 
Germany Ag Plasma 
PBMCs 
Recurrent 
depressive and 
bipolar disorders 
Other depressive 
and anxiety 
disorders 
Psychotic disorders
10 
 
11 
 
11 
53 samples 
(collected in a 
week), 20 
positive 
Sauder  
et al., 1996 
Germany RT-PCR/RNA Plasma 
PBMCs 
Psychiatric 
disorders 
Control 
26 
23 
13/50% 
0/0% 
Kubo  
et al., 1997 
Japan RT-PCR/RNA Plasma 
PBMCs 
Psychiatric patients
Control 
106 
12 
0.2% 
0/0% 
Salvatore  
et al., 1997 
USA, 
Europe 
RT-PCR/RNA Brain Neuropsychiatric 
disorders 
75 11/14.7% 
Lieb  
et al., 1997 
Germany RT-PCR/RNA Plasma 
PBMCs 
Psychiatric 
disorders  
159 0/0% 
Czygan  
et al., 1999 
Germany RT-PCR/RNS Brain Neuropsychiatric 
disorders 
Control 
86 
 
52 
0/0% 
 
0/0% 
Vahlenkamp 
et al., 2000 
Germany RT-PCR/RNA Plasma 
PBMCs 
Psychiatric patients
Control 
27 
13 
10/37% 
2/15.4% 
Rybakowski  
et al., 2001 
Poland ECLIA/Ab Serum Psychiatric patients
 
946 23/2.4% 
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Authors Country Method/marker Sample Diagnosis  Total No No and % of 
positive 
Rackova  
et al., 2003 
Czech 
Republic 
ELISA/CIC Plasma Affective and 
schizophrenic 
disorders 
Control 
46 
 
 
126 
12/26.1% 
 
 
22.2% 
Miranda  
et al., 2006 
Brazil RT-PCR/RNA Plasma 
PBMCs 
Schizophrenia and 
affective disorders 
Control 
30 
 
30 
10/33.3% 
 
4/13.3% 
Matsunaga  
et al., 2008 
Japan RIA/Ab Serum Psychiatric patients
Control 
304 
378 
No significant 
difference 
Rackova  
et al., 2009 
Czech 
Republic 
ELISA/CIC Plasma Affective and 
schizophrenic 
disorders 
Control 
39 
 
 
126 
26/66.7% 
 
 
28/22.2% 
Karakose  
et al., 2011 
Turkey ELISA/Ab Serum Psychiatric 
disorders 
Control 
131 
137 
17/12.98% 
19/13.86% 
Karakose  
et al., 2011 
Turkey RT-PCR/RNA 
 
Plasma 
PBMCs 
Psychiatric 
disorders 
Control 
131 
137 
0/0% 
0/0% 
Table 8. Studies that detected BDV infection in psychiatric patients 
3.7 Borna diasease virus and other disorders   
The influence of BDV infection on other disorders was also studied, particularly on 
neurological and infectious diseases. Prudlo and colleagues did not find any increase in 
BDV Ab positivity in neurologic patients (with amyotrophic lateral sclerosis) compared to 
surgical patients (Prudlo et al., 2002). Li and colleagues detected BDV RNA in patients with 
viral encephalitis, but no BDV positivity was found in other neurological disorders (Li et al., 
2009; Salvatore et al., 1997). Flower and colleagues reported higher rates of BDV CIC 
positivity in multitransfused patients (Flower et al., 2008), and BDV RNA and Ag were 
detected in the cerebrospinal fluid of patients with multiple sclerosis (Deuschle et al., 1998). 
A higher rate of BDV positivity was not detected in patients with epilepsy (Czygan et al., 
1999; Hofer et al., 2006) or Parkinson’s disease (Haga et al., 1997). Several studies detected 
higher rates of BDV infection positivity in HIV-positive patients (Auwanit et al., 1996; Bode 
et al., 1992; Cotto et al., 2003) but not in therapeutically immunosuppressed patients (Cotto 
et al., 2003). 
4. Conclusions  
The Borna disease virus is a neurotropic RNA virus belonging to the family Bornaviridae, 
order Mononegavirales, which has a high affinity for the central nervous system, especially 
for limbic structures. The Borna disease virus causes an infection in birds and mammals 
including humans. Some infected animals develop symptoms which are very similar to 
human psychiatric disorders (cognitive impairment, behavioural changes, changes in social 
behaviour, appetite, sleeping...). Because of this similarity BDV has begun to be associated 
with several psychiatric disorders, especially with mood and psychotic disorders. The 
association of BDV and psychiatric disorders is explained by the viro-psycho-
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immunological disease model. A BDV persistent infection of the central nervous system is 
activated by changes in the immune system, an activated BDV infection  influences 
neurotransmitter functions and contributes to the onset of psychiatric disorders in 
vulnerable individuals (with a genetic predisposition).  
In the 1980s the presence of a BDV infection was found in patients with neuropsychiatric 
disorders. Since the 1980s many studies have detected a BDV infection in patients with 
psychiatric disorders (the majority of them tested BDV positive in affective disorders and 
schizophrenia) and in patients with neurological disorders, HIV infection and others. The 
positivity of a BDV infection ranges from negative results to very high positivity rates, more 
than 90% in patients with affective disorders in comparison with BDV positivity between 
0%-40% in healthy individuals. The Borna disease virus positivity in psychiatric patients 
ranges from negative to highly positive. These differences in positivity can be caused by 
several factors; features of the psychiatric population (age, diagnosis, severity of the 
psychopathology, immune status), geographical region, differences in specificity and 
sensitivity of the laboratory methods used and others. The significantly higher rates of BDV 
positivity were detected in younger individuals, especially in children. Several research 
groups reported an association between higher BDV positivity and the severity of the 
psychopathology.The high variability of BDV positivity in humans can be influenced by the 
laboratory method used. The detection of BDV CIC by ELISA has shown a 10-fold higher 
incidence of BDV infection than was estimated for BDV Ab positivity by the 
immunofluorescence method. 
4.1 Arguments supporting the association of BDV infection with psychiatric disorders 
include 
Characteristics of the Borna disease virus - its ability to infect and spread through the central 
nervous system, causing persistent infection and its activation, have led to the connection 
with psychiatric disorders.  An experimental BDV infection shows the influence of BDV on 
neurotransmitter receptors which lead to behavioural changes, cognitive impairment and 
neurological disturbances. 
Many studies have detected the significantly higher BDV positivity in psychiatric patients in 
comparison with healthy individuals. The Borna disease virus was isolated from PBMCs in 
plasma, cerebrospinal fluid and brain tissue. Higher levels of BDV antigens and circulating 
immunocomplexes have been found in acutely depressed patients than in patients with mild 
depression. Levels of BDV antigens and circulating immunocoplexes correlate with the 
severity of psychiatric symptoms. Depressed patients who were treated with virostatic 
medication – amantadine, improved their psychopathology significantly and more quickly. 
The improvement of depression symptoms correlates with the decrease or disappearance of 
BDV positivity (levels of antigens). 
4.2 Arguments against the BDV role in ethiopathology in psychiatric disorders 
include 
Many studies have failed to detect BDV infection in psychiatric patients or did not find 
significant differences in BDV positivity between psychiatric patients and healthy 
individuals. Some researchers detected high BDV positivity in healthy individuals and 
considered BDV infection to be a normal part of human life without any influence on 
health. 
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There are reports about the effect of antiviral treatment with amantadine in BDV positive 
patients with depression disorders.  The improvement of depression symptomatology 
during this treatment could be explained by the antidepressive effect of amantadine. Some 
studies did not prove the virostatic effect of amantadine in the treatment a BDV infection. 
Several studies criticize the unreliability of some laboratory methods, in these studies BDV 
was not isolated from BDV CIC positive samples.  
What can we conclude? The role of BDV in psychiatric disorders is still unclear. But very 
probably this infection can be involved in the onset and the course of psychiatric disorders 
in a determinate subpopulation of psychiatric patients. German and Italian researchers 
examined the presence of BDV infection in children. These studies are crucial to obtaining 
information about the possible influence of neurotropic viruses on brain development. A 
BDV infection in early life can contribute to the onset of psychiatric disorders in adults in 
predisposed individuals. 
For future research, which is important for answering still unclear questions about the 
Borna disease virus we need more and larger studies testing comparable patient groups and 
using comparable laboratory methods. We are also missing more double-blind studies with 
amantadine in BDV positive psychiatric patients. Studies testing for a BDV infection from 
childhood to adulthood are necessary to answer the question: What is first?: BDV infection 
and secondly the development of psychiatric disorders or first psychiatric disorders which  
secondarily leads to several changes in the immune system and then the activation of the 
BDV infection.  
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